Cathepsin K expression and activity in Canine osteosarcoma

Journal of Veterinary Internal Medicine

Volumn 26, Issue 1, 2012, Pages 126-134

  Schmit, J M ^a   Pondenis, H C ^a   Barger, A M ^a   Borst, L B ^b   Garrett, L D ^a   Wypij, J M ^a   Neumann, Z L ^a   Fan, T M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Bone resorption; Cysteine protease; Malignant osteolysis; Surrogate marker

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CATHEPSIN K; COLLAGEN TYPE 1; RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; BONE TUMOR; CHEMISTRY; DOG; DOG DISEASE; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; OSTEOSARCOMA; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CATHEPSIN K; CELL LINE, TUMOR; COLLAGEN TYPE I; DOG DISEASES; DOGS; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMALIA; CANIS FAMILIARIS;

EID: 84855749981     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00834.x     Document Type: Article

References (36)

1. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004;385:1017-1027.
2. Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004;3:1516-1619.
3. Mohamed MM, Sloane BF. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775.
4. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010;120:3421-3431.
5. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996;271:12517-12524.
6. Saftig P, Hunzikder E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998;95:13453-13458.
7. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-251.
8. Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010;10:452-458.
9. Le Gall C, Bellahcene A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-9902.
10. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009;86:175-182.
11. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57:5386-5390.
12. Quintanilla-Dieck MJ, Codriansky K, Keady M, et al. Cathepsin K in melanoma invasion. J Invest Dermatol 2008;128:2281-2288.
13. Lindeman JH, Hanemaaijer R, Mulder A, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593-600.
14. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18:222-230.
15. Soderstrom M, Ekfors T, Bohling T, et al. Cysteine proteinases in chondrosarcomas. Matrix Biol 2001;19:717-725.
16. Husmann K, Muff R, Bolander ME, et al. Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis. Mol Carcinog 2008;47:66-73.
17. Fan TM, Charney SC, de Lorimier LP, et al. Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med 2009;23:152-160.
18. Fan TM, de Lorimier LP, Garrett LD, Lacoste HI. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med 2008;22:380-387.
19. Fan TM, de Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007;21:431-439.
20. Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc 2004;225:1567-1572, 1548.
21. Ramirez O, 3rd, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
22. McQueney MS, Amegadzie BY, D'Alessio K, et al. Autocatalytic activation of human cathepsin K. J Biol Chem 1997;272:13955-13960.
23. Mandelin J, Hukkanen M, Li TF, et al. Human osteoblasts produce cathepsin K. Bone 2006;38:769-777.
24. George M, Stein B, Muller O, et al. Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts. Ann Rheum Dis 2004;63:67-70.
25. Mulari MT, Qu Q, Harkonen PL, Vaananen HK. Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif Tissue Int 2004;75:253-261.
26. Takahashi T, So S, Wang D, et al. Phagocytosis of different matrix components by different cell types at bone-forming sites in cultured mouse calvariae. Cell Tissue Res 1986;245:9-17.
27. Takahashi T, Kurihara N, Takahashi K, Kumegawa M. An ultrastructural study of phagocytosis in bone by osteoblastic cells from fetal mouse calvaria in vitro. Arch Oral Biol 1986;31:703-706.
28. Canalis E, McCarthy TL, Centrella M. Growth factors and cytokines in bone cell metabolism. Annu Rev Med 1991;42:17-24.
29. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop Relat Res 1991;263:30-48.
30. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-178.
31. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003;415:S32-S38.
32. Tumminello FM, Flandina C, Crescimanno M, Leto G. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: Clinical and therapeutic implications. Biomed Pharmacother 2008;62:130-135.
33. Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 2006;2:1-10.
34. Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 2009;64:188-192.
35. Prezelj J, Ostanek B, Logar DB, et al. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women. Menopause 2008;15:369-373.
36. Lacoste H, Fan TM, de Lorimier LP, Charney SC. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335-341.